Embecta (NASDAQ:EMBC) CEO Purchases $141,000.00 in Stock

Embecta Corp. (NASDAQ:EMBC) CEO Devdatt Kurdikar acquired 30,000 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was purchased at an average cost of $4.70 per share, with a total value of $141,000.00. Following the purchase, the chief executive officer owned 804,919 shares of the company’s stock, valued at $3,783,119.30. The trade was a 3.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Embecta Price Performance

Shares of EMBC traded up $0.41 during mid-day trading on Thursday, reaching $5.16. 659,113 shares of the company’s stock traded hands, compared to its average volume of 1,586,592. The stock’s 50-day moving average is $3.43 and its two-hundred day moving average is $6.46. Embecta Corp. has a 12 month low of $2.77 and a 12 month high of $15.55. The stock has a market cap of $292.08 million, a P/E ratio of 3.49 and a beta of 0.81.

Embecta (NASDAQ:EMBC) last released its earnings results on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.29. The business had revenue of $271.70 million during the quarter, compared to the consensus estimate of $254.53 million. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.The business’s revenue for the quarter was down 8.1% compared to the same quarter last year. During the same period last year, the company earned $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. Research analysts predict that Embecta Corp. will post 1.85 earnings per share for the current year.

Embecta Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th will be paid a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Thursday, August 27th. Embecta’s dividend payout ratio is currently 2.70%.

Embecta News Summary

Here are the key news stories impacting Embecta this week:

• Negative Sentiment: The lawsuit, filed in federal court in New Jersey, alleges that Embecta and certain executives misrepresented the commercial stability of the company’s insulin pen-needle business. The allegations concern investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, and have not been proven in court. EMBC Securities Lawsuit: Embecta Securities Fraud Class Action is Pending
• Negative Sentiment: A wave of investor-alert releases from SBS Law, Kaplan Fox, DJS Law, Rosen Law Firm, Hagens Berman, Faruqi & Faruqi and other firms highlights an August 17, 2026 deadline for investors to seek lead-plaintiff status. The repeated announcements increase the visibility of the legal issue and could raise concerns about potential financial, management and reputational costs for Embecta. Kaplan Fox Alerts Investors of a Securities Class Action Against Embecta
• Neutral Sentiment: The announcements primarily seek potential plaintiffs and do not represent a new court ruling, settlement or regulatory finding. Embecta’s previously reported quarterly results showed adjusted earnings and revenue above consensus, but revenue declined 8.1% year over year; the company’s FY 2026 earnings guidance remains $1.80–$1.90 per share.

Hedge Funds Weigh In On Embecta

A number of large investors have recently added to or reduced their stakes in EMBC. Royal Bank of Canada increased its stake in Embecta by 38.3% during the 1st quarter. Royal Bank of Canada now owns 18,201 shares of the company’s stock valued at $232,000 after purchasing an additional 5,036 shares in the last quarter. AQR Capital Management LLC raised its stake in Embecta by 3.7% in the 1st quarter. AQR Capital Management LLC now owns 225,641 shares of the company’s stock worth $2,738,000 after acquiring an additional 8,109 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Embecta by 2.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock valued at $629,000 after purchasing an additional 1,159 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Embecta by 4.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 172,173 shares of the company’s stock valued at $2,195,000 after purchasing an additional 7,894 shares during the period. Finally, Jane Street Group LLC increased its holdings in Embecta by 224.0% in the 1st quarter. Jane Street Group LLC now owns 132,688 shares of the company’s stock worth $1,692,000 after buying an additional 91,729 shares during the period. 93.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on EMBC. BTIG Research downgraded shares of Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Weiss Ratings lowered Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Mizuho lowered their target price on Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Wall Street Zen downgraded Embecta from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Bank of America cut their price target on Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research note on Monday, May 18th. Three analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $11.00.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.